Dexmedetomidine-esketamine-ropivacaine Versus Sufentanil-ropivacaine for Epidural Labor Analgesia
Launched by PEKING UNIVERSITY FIRST HOSPITAL ยท
Trial Information
Current as of November 14, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different combinations of medicines used to relieve pain during labor through an epidural, which is a common method to help manage labor pain. One combination uses medicines called sufentanil and ropivacaine, which is commonly used but can sometimes cause side effects. The other combination being tested includes dexmedetomidine, esketamine, and ropivacaine. Both new and standard combinations have been shown to work well for pain relief, and this study aims to see if the new combination is just as effective and safe as the standard one.
Women who are planning to have an epidural during labor may be eligible to take part in this study. While the trial has not started recruiting yet, it is designed for adult women of childbearing age. Participants can expect to receive one of the two medicine combinations through an epidural to help manage labor pain, and researchers will monitor how well the pain relief works and whether there are any side effects. This small initial study will help doctors understand if a larger study is possible in the future.
Gender
FEMALE
Eligibility criteria
About Peking University First Hospital
Peking University First Hospital is a leading medical institution in China, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its extensive expertise in various medical fields to conduct rigorous studies aimed at improving patient outcomes and contributing to global medical knowledge. With a multidisciplinary team of skilled researchers and clinicians, Peking University First Hospital is dedicated to the ethical conduct of clinical research, ensuring the highest standards of safety and efficacy in its trials. The institution plays a vital role in translating scientific discoveries into effective treatments, thereby enhancing the quality of care for patients both locally and worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Dong-Xin Wang, MD,PhD
Principal Investigator
Peking University First Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported